Accessibility Menu
Polyrizon logo

Polyrizon(NASDAQ) PLRZ

Market Cap$26.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-99%
5 YearN/A
1 Year+99%
1 Month+23%
$12.56
+0.40%
+0.05Today
Polyrizon last closing stock price
MetricPriceDate
Last closeUSD 12.562026-09-03
Polyrizon stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.88%USD 12.802026-08-27
1 month+23.14%USD 10.202026-08-04
3 month-3.31%USD 12.992026-06-05
Year to date+47.94%USD 8.492025-12-31
1 year+99.37%USD 6.302025-09-03
Since inception-99.46%USD 2,325.002024-10-29

Polyrizon Financials at a Glance

Market Cap

$26.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$3.34M

EPS (TTM)

-$2.70

P/E Ratio

-4.65

Dividend

$0.00

Beta (Volatility)

-0.78 (Low)

Price

$12.56

Volume

134,417.128

Open

$12.00

Previous Close

$12.56

Daily Range

$11.95 - $13.28

52-Week Range

$2.88 - $18.20

Estimated Earnings Date

Jul 1, 2026

PLRZ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Polyrizon

Polyrizon Ltd. is an innovative Israeli biotechnology company focused on developing medical device hydrogels delivered as nasal sprays. These sprays aim to create a protective barrier in the nasal cavity, preventing viruses and allergens from adhering to the nasal epithelial tissue. The company is advancing several products targeting various health concerns, including allergies and viral infections.

Products and Services
  • PL-14: Aimed at blocking nasal allergies
  • PL-15: Targeted solution for COVID-19 prevention
  • PL-16: Designed for influenza prevention
Growth Outlook
  • Strong pipeline with multiple products in development
  • Increasing demand for innovative healthcare solutions
  • Potential for strategic partnerships to enhance market reach
Financial Highlights
  • Recent quarterly net income of -$3.16 million
  • Cash and short-term investments totaling $12.27 million
  • Current ratio of 29.03 indicates strong liquidity position
Polyrizon Ltd. operates in a promising sector, leveraging cutting-edge technology to address significant health challenges. The company's focus on nasal spray solutions positions it well within the growing biotechnology industry. With a robust product pipeline and a commitment to innovation, Polyrizon is poised for potential growth. Recent financial data reflects a solid liquidity position, which may support ongoing research and development efforts. The company’s strategic direction and product offerings could attract interest from investors looking for opportunities in the healthcare sector.
AI Generated • Aug 21, 2026

Industry

Biotechnology

Sector

Health Care

Employees

6

CEO

Tomer Izraeli, MBA

Website

polyrizon-biotech.com

Headquarters

Ra'anana, TA 4321545, IL

PLRZ Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-16.94%

Return on Capital

-29.77%

Return on Assets

-15.56%

Earnings Yield

-21.51%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$26.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.08M

Volume

134.42K

Avg. Volume

60.57K

Financials (TTM)

Gross Profit

-$342.00K

Operating Income

-$6.25M

EBITDA

-$5.91M

Operating Cash Flow

-$4.06M

Capital Expenditure

-$7.50K

Free Cash Flow

-$4.07M

Cash & ST Invst.

$12.27M

Total Debt

$0.00

Polyrizon Performance Analysis

Polyrizon annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Polyrizon sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31N/A
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Polyrizon annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -278.589.6%
20232023-12-31USD -214.58-23.0%
20242024-12-31USD -552.51157.5%
20252025-12-31USD -2.07-99.6%
Polyrizon sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-3199.8%
Q22025-06-30N/A
Q32025-09-30-2200.2%
Q42025-12-31-39.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$153.00K

-30.8%

Gross Margin

0.00%

N/A

Market Cap

$26.17MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.36M

N/A

Employees

6

N/A

Net Income

-$3.16M

-230.0%

EBITDA

-$3.61M

-330.9%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$12.27M

+380.5%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-15.56%

N/A

Return on Invested Capital

-29.77%

N/A

Free Cash Flow

-$2.71M

-234.8%

Operating Cash Flow

-$2.71M

-234.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CYCNCyclerion Therapeutics, Inc.
$4.96+9.73%
KTTAPasithea Therapeutics Corp.
$0.58+0.02%
VYNEVYNE Therapeutics Inc.
$28.56+0.00%
QNRXQuoin Pharmaceuticals, Ltd.
$7.87+16.77%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$10.38+0.11%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$106.74+0.00%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$51.60-0.00%
IBITiShares Bitcoin Trust
$46.35+0.06%

Questions About PLRZ

What is the current price of Polyrizon?

Polyrizon is trading at $12.56 per share.

What is the 52-week range for Polyrizon?

Over the past 52 weeks, Polyrizon has traded between $2.88 and $18.20.

How much debt does Polyrizon have?

As of the most recent reporting period, Polyrizon reported total debt of $0.00.

How much cash does Polyrizon have on hand?

Polyrizon reported $1.31M in cash and cash equivalents in its most recent financial results.

What is Polyrizon’s dividend yield?

Polyrizon does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services